When asked why the company decided to make the acquisition, WCG Chairman and CEO Donald A. Deieso, PhD, told Outsourcing-Pharma.com: “Our clients have consistently asked for assistance in creating a more efficient process of developing research budgets for each site and in negotiating the contracts between the drug company and the sites, and manage the payments between the parties.”
With Clintrax Global as a part of its family of companies, WCG will have access to the Clintrax’s technology-driven process for negotiating clinical trial-related contacts between companies.
“We are committed to creating a broad suite of solutions that assist biopharmaceutical companies and CROs in more efficiently starting up clinical trials. Clintrax adds an important element to our suite,” added Deieso. “By reducing study start up time, our clients will conserve time, resources, and expense – with the benefit that more R&D can be devoted to addressing other diseases.”
As part of the acquisition, Clintrax Global will continue to operate as an independent company.
“Our team is excited to join the WCG family,” said Clintrax Global CEO Brandon Evans. “We are confident that – as part of the WCG family – we will have the opportunity to impact global health on an even greater scale.”
Financial details about the transaction were not disclosed.